



Curriculum Vitae Europass

Name **Maria Gabriella Parma**
Address Istituto Europeo di Oncologia - via Ripamonti 435 - MILAN

Phone number 02 5789540 - 543
E-mail gabriella.parma@ieo.it

Citizenship Italian

Date and place of birth 5th January 1966, Monza - Italy

Education

1996-1999 Università La Sapienza Roma
PhD in Gynecology Oncology

1991-1995 Università Bicocca, Milano
Board Certification in Obstetrics and Gynecology

1985-1991 Università di Milano
Medicine and Surgery Degree

1980-1985 High School (Liceo Scientifico Banfi – Vimercate – MB)

Internships

1990-1991 Undergraduate training – Dept of Obstetrics and Gynecology - S. Gerardo Hospital – Monza
University of Milano

1991-1995 Postgraduate training – Dept of Obstetrics and Gynecology – H.S.Gerardo – Monza -
University of Milano

1996-1999 Fellowship – Dept of Gynecology – IEO – Milan

Stage

01.1994-06.1994 Frequency at Dept of Medical Oncology (Prof. Cavalli) – S. Giovanni Hospital –
Bellinzona – Switzerland

03.1998-04.1998 Frequency Frequency at Dept of Obstetrics and Gynecology (Director K. Hatc) –
University Hospital – Tucson – Arizona – USA

Previous Employment

1999-2004 Assistant - Dept of Gynecology – IEO – Milan

2004-2015 Deputy Director - Dept of Gynecology – IEO – Milan

Current position

Deputy Director and Clinical Trial Coordinator in gynecology oncology
Dept. of Gynecology
IEO – Via Ripamonti 435, Milan

Milano, 30.09.2018

Publications

1. Neoadjuvant chemotherapy in cervical cancer: an update. Lapresa M, Parma G, Portuesi R, Colombo N. *Expert Rev Anticancer Ther.* 2015;15(10):1171-81. doi: 10.1586/14737140.2015.1079777. Epub 2015 Sep 7. Review.
2. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience. Landoni F, Zanagnolo V, Rosenberg PG, Lopes A, Radice D, Bocciolone L, Aletti G, Parma G, Colombo N, Maggioni A. *Gynecol Oncol.* 2013 Jul;130(1):69-74. doi: 10.1016/j.ygyno.2013.02.038. Epub 2013 Mar 6.
3. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Lee CK, Simes RJ, Brown C, GebSKI V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M. *Ann Oncol.* 2013 Apr;24(4):937-43. doi: 10.1093/annonc/mds538. Epub 2012 Oct 26.
4. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N. *Int J Gynecol Cancer.* 2012 Jun;22(5):792-800.
5. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, GebSKI V, Pfisterer J, Pujade-Lauraine E, Friedlander M. *Br J Cancer.* 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13.
6. Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer. An Italian experience. Maneo A, Sideri M, Scambia G, Boveri S, Dell'anna T, Villa M, Parma G, Fagotti A, Fanfani F, Landoni F. *Gynecol Oncol.* 2011 Dec;123(3):557-60. doi: 10.1016/j.ygyno.2011.08.009. Epub 2011 Sep 9.
7. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. Fruscio R, Garbi A, Parma G, Lissoni AA, Garavaglia D, Bonazzi CM, Dell'anna T, Mangioni C, Milani R, Colombo N. *J Natl Cancer Inst.* 2011 Feb 16;103(4):347-51. doi: 10.1093/jnci/djq530. Epub 2011 Jan 7.
8. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M; ESMO Guidelines Working Group. *Ann Oncol.* 2010 May;21 Suppl 5:v23-30. doi: 10.1093/annonc/mdq244. No abstract available.
9. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaròs D, Lhommé C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla JP. *Ann Oncol.* 2010 Apr;21(4):759-65. doi: 10.1093/annonc/mdp514. Epub 2009 Nov 11.
10. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E. *Ann Oncol.* 2009 Apr;20(4):660-5. doi: 10.1093/annonc/mdn690. Epub 2009 Jan 30.
11. Chemo-conization in early cervical cancer. Landoni F, Parma G, Peiretti M, Zanagnolo V, Sideri M, Colombo N, Maggioni A. *Gynecol Oncol.* 2007 Oct;107(1 Suppl 1):S125-6. Epub 2007 Aug 29.
12. Management of ovarian stromal cell tumors. Colombo N, Parma G, Zanagnolo V, Insinga A. *J Clin Oncol.* 2007 Jul 10;25(20):2944-51. Review.
13. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Colombo N, Formelli F, Cantù MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A. *Cancer Epidemiol Biomarkers Prev.* 2006 Oct;15(10):1914-9.

14. Ovarian cancer. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. *Crit Rev Oncol Hematol*. 2006 Nov;60(2):159-79. Epub 2006 Oct 2. Review.
15. Role of conservative surgery in ovarian cancer: the European experience. Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni A. *Int J Gynecol Cancer*. 2005 Nov-Dec;15 Suppl 3:206-11. Review.
16. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C. *Neurology*. 2003 Nov 11;61(9):1297-300.
17. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. *J Clin Oncol*. 2002 Mar 1;20(5):1232-7.
18. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. *Forum (Genova)*. 2000 Oct-Dec;10(4):323-32. Review.
19. Role of chemotherapy in relapsed ovarian cancer. Colombo N, Parma G, Bocciolone L, Sideri M, Franchi D, Maggioni A. *Crit Rev Oncol Hematol*. 1999 Dec;32(3):221-8. Review. No abstract available.
20. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Zanetta G, Fei F, Parma G, Balestrino M, Lissoni A, Gabriele A, Mangioni C. *Ann Oncol*. 1999 Oct;10(10):1171-4.
21. First-line chemotherapy in advanced ovarian cancer. Colombo N, Parma G, Caspani G, Donesana P, Marinetti E, Mangioni C. *Tumori*. 1999 May-Jun;85(3 Suppl 1):S23-6. Review. Italian. No abstract available.
22. An active chemotherapy regimen for advanced ovarian sex cord-stromal tumors. Colombo N, Parma G, Franchi D. *Gynecol Oncol*. 1999 Feb;72(2):129-30. No abstract available.
23. A randomized comparison of continuous versus interrupted mass closure of midline incisions in patients with gynecologic cancer. Colombo M, Maggioni A, Parma G, Scalabrino S, Milani R. *Obstet Gynecol*. 1997 May;89(5 Pt 1):684-9.
24. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Ferdeghini M, Parma G, Cristofani R. *Int J Gynecol Cancer*. 1997 Jan;7(1):78-83.
25. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. *Ann Oncol*. 1996 Oct;7(8):861-3.
26. Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Marzola M, Parma G, Bonazzi C, Colombo N, Maneo A, Pittelli MR, Mangioni C. *Ann Oncol*. 1996 Apr;7(4):419-21.
27. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Cormio G, Maneo A, Parma G, Pittelli MR, Miceli MD, Bonazzi C. *Ann Oncol*. 1995 Jul;6(6):571-4.
28. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer. Sessa C, Pagani O, Parma G, Goldhirsch A, Cavalli F. *Semin Oncol*. 1995 Jun;22(3 Suppl 6):112-7.
29. Options for primary chemotherapy in advanced ovarian cancer: the European perspective. Colombo N, Maggioni A, Vignali M, Parma G, Mangioni C. *Gynecol Oncol*. 1994 Dec;55(3 Pt 2):S108-13. Review.
30. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Cavaletti G, Bogliun G, Marzorati L, Tredici G, Colombo N, Parma G, Miceli MD. *Anticancer Res*. 1994 May-Jun;14(3B):1287-92.